Related Pages for PIIND
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
PIIND
Related News - PIIND
PI Industries: Jefferies on PI Industries Maintains Buy with Target Price of ₹2,910 as revenue was in line but EBITDA/PAT missed estimates by 8%/15%, CSM exports faced lower volumes and pricing pressure, Pharma remained weak, FY27 growth guidance was cut to low-single-digit from high-single-digit, and FY27/FY28 EPS estimates were reduced 12%/11%.
13 Aug 2026 09:05 AM
PI Industries: Jefferies on PI Industries Maintains Buy with Target Price of ₹2,910 as revenue was in line but EBITDA/PAT missed estimates by 8%/15%, CSM exports faced lower volumes and pricing pressure, Pharma remained weak, FY27 growth guidance was cut to low-single-digit from high-single-digit, and FY27/FY28 EPS estimates were reduced 12%/11%.
PI Industries: HSBC on PI Industries Maintains Hold with Target Price cut to ₹2,720 as 1Q earnings missed again due to weak exports, higher costs and lower realisations, core businesses remain muted while new businesses require investment, though the stock has corrected 24% in six months and trades at 28x FY28E EPS versus a 32x 10-year mean.
13 Aug 2026 09:05 AM
PI Industries: HSBC on PI Industries Maintains Hold with Target Price cut to ₹2,720 as 1Q earnings missed again due to weak exports, higher costs and lower realisations, core businesses remain muted while new businesses require investment, though the stock has corrected 24% in six months and trades at 28x FY28E EPS versus a 32x 10-year mean.
PI Industries: Citi on PI Industries Maintains Sell with Target Price of ₹2,375 as 1Q EBITDA fell 29% YoY on 13% lower Agro CSM exports and weak margins, higher Pharma and biologicals losses hurt earnings, while generic competition and front-ended pyroxasulfone sales create near-term uncertainty.
13 Aug 2026 09:05 AM
PI Industries: Citi on PI Industries Maintains Sell with Target Price of ₹2,375 as 1Q EBITDA fell 29% YoY on 13% lower Agro CSM exports and weak margins, higher Pharma and biologicals losses hurt earnings, while generic competition and front-ended pyroxasulfone sales create near-term uncertainty.
Pi Industries: Co Seeing Some Sequential Delays In Pharma Business Order Book. - Concall Update
12 Aug 2026 12:47 PM
Pi Industries: Co Seeing Some Sequential Delays In Pharma Business Order Book. - Concall Update
Pi Industries: Co See Growth Opportunities Across Brazil, Mexico, Europe, U.S - Concall Update
12 Aug 2026 12:18 PM
Pi Industries: Co See Growth Opportunities Across Brazil, Mexico, Europe, U.S - Concall Update
PI Industries: Co Reports Many Molecules in R&D and CSM With 2-3 New Products Coming Soon. - Concall Update
12 Aug 2026 12:22 PM
PI Industries: Co Reports Many Molecules in R&D and CSM With 2-3 New Products Coming Soon. - Concall Update
PI Industries: Keeps FY27 Revenue Growth Guidance at Low Single Digits - Concall Update
12 Aug 2026 12:23 PM
PI Industries: Keeps FY27 Revenue Growth Guidance at Low Single Digits - Concall Update
Pi Industries: Demand Challenges Automatically Put Pressure On Prices Q1 - Concall Update
12 Aug 2026 12:25 PM
Pi Industries: Demand Challenges Automatically Put Pressure On Prices Q1 - Concall Update
Pi Industries: Trying To Optimise Product Mix, With Margins Under Pressure - Concall Update
12 Aug 2026 12:27 PM
Pi Industries: Trying To Optimise Product Mix, With Margins Under Pressure - Concall Update
Pi Industries: Company Will Hold Q1 Earnings Call On August 12 At 12 PM
03 Aug 2026 09:37 PM
Pi Industries: Company Will Hold Q1 Earnings Call On August 12 At 12 PM
PI Industries: Jefferies on PI Industries Buy, Target Price ₹3,575, citing upcoming monetization of agchem and biological innovation platforms, long-term investments in Pharma CRDMO and semiconductor chemicals, accelerating growth, and an expected 12% adjusted PAT CAGR over FY26–28.
01 Jul 2026 09:08 AM
PI Industries: Jefferies on PI Industries Buy, Target Price ₹3,575, citing upcoming monetization of agchem and biological innovation platforms, long-term investments in Pharma CRDMO and semiconductor chemicals, accelerating growth, and an expected 12% adjusted PAT CAGR over FY26–28.
PI Industries: Citi maintains a Sell on PI Industries with a Target Price of ₹2,600, noting key customer Kumiai’s improved near-term outlook from advanced Axeev shipments and strong fine chemicals sales leading to flat YoY Feb–Apr’26 revenues, though full-year guidance remains unchanged.
10 Jun 2026 08:53 AM
PI Industries: Citi maintains a Sell on PI Industries with a Target Price of ₹2,600, noting key customer Kumiai’s improved near-term outlook from advanced Axeev shipments and strong fine chemicals sales leading to flat YoY Feb–Apr’26 revenues, though full-year guidance remains unchanged.
Pi Industries: Kumiai Raises H12026 Profit Projections With A 70.5% Increase In Operating Profit Estimate. - NDTV Profit
09 Jun 2026 11:45 AM
Pi Industries: Kumiai Raises H12026 Profit Projections With A 70.5% Increase In Operating Profit Estimate. - NDTV Profit
Pi Industries: Co Main Client Kumiai Raises Its Forecast
09 Jun 2026 11:43 AM
Pi Industries: Co Main Client Kumiai Raises Its Forecast
PI Industries: Jefferies maintains a Buy on PI Industries with a Target Price of ₹3575, citing Q4 EBITDA and PAT miss due to slower new product growth and sharp contraction in pyroxasulfone along with higher working capital, but expects FY27 recovery from a favorable base and new molecule growth, projecting a 12% adjusted PAT CAGR over FY26–28.
21 May 2026 08:53 AM
PI Industries: Jefferies maintains a Buy on PI Industries with a Target Price of ₹3575, citing Q4 EBITDA and PAT miss due to slower new product growth and sharp contraction in pyroxasulfone along with higher working capital, but expects FY27 recovery from a favorable base and new molecule growth, projecting a 12% adjusted PAT CAGR over FY26–28.
PI Industries: HSBC maintains a Hold on PI Industries with a Target Price of ₹3000, citing another weak Q4FY26 earnings miss due to agri business disappointment and higher overheads pressuring margins, while noting uncertainty around muted core businesses and slower scaling of new businesses leading to earnings cuts.
21 May 2026 08:53 AM
PI Industries: HSBC maintains a Hold on PI Industries with a Target Price of ₹3000, citing another weak Q4FY26 earnings miss due to agri business disappointment and higher overheads pressuring margins, while noting uncertainty around muted core businesses and slower scaling of new businesses leading to earnings cuts.
PI Industries: Citi maintains a Sell on PI Industries with a Target Price of ₹2600, citing weak Q4 EBITDA due to lower CSM exports and agchem revenues, continued losses in Pharma CDMO despite growth, margin pressure, back-ended FY27 recovery expectations, and concerns over pyroxasulfone generic competition and muted agchem outlook.
21 May 2026 08:53 AM
PI Industries: Citi maintains a Sell on PI Industries with a Target Price of ₹2600, citing weak Q4 EBITDA due to lower CSM exports and agchem revenues, continued losses in Pharma CDMO despite growth, margin pressure, back-ended FY27 recovery expectations, and concerns over pyroxasulfone generic competition and muted agchem outlook.
PI Industries: DAM Capital maintains a Sell on PI Industries with a Target Price of ₹2556, citing structural challenges in Agchem CSM, sharp slowdown in legacy exports, weak domestic agchem demand, delayed recovery in Biologicals and exports, margin pressure from higher costs and R&D spend, and EPS cuts for FY27/FY28 due to muted growth outlook.
21 May 2026 08:53 AM
PI Industries: DAM Capital maintains a Sell on PI Industries with a Target Price of ₹2556, citing structural challenges in Agchem CSM, sharp slowdown in legacy exports, weak domestic agchem demand, delayed recovery in Biologicals and exports, margin pressure from higher costs and R&D spend, and EPS cuts for FY27/FY28 due to muted growth outlook.
PI Industries: Morgan Stanley maintains an Overweight on PI Industries with a Target Price of ₹3,883, citing expected return to revenue growth in FY27 driven by improving exports and domestic agchem traction, strong biologicals margins, pharma scale-up potential, US approval for its bionematocide product, and upcoming Pioxaniliprole launch in India.
21 May 2026 08:53 AM
PI Industries: Morgan Stanley maintains an Overweight on PI Industries with a Target Price of ₹3,883, citing expected return to revenue growth in FY27 driven by improving exports and domestic agchem traction, strong biologicals margins, pharma scale-up potential, US approval for its bionematocide product, and upcoming Pioxaniliprole launch in India.
PI Industries: Focuses On Increasing Market Share Through Volume Growth Rather Than Margin Growth, Aiming For Revenue Of Rs 100 Million From Electronic Chemicals In 4-5 Years.
20 May 2026 03:37 PM
PI Industries: Focuses On Increasing Market Share Through Volume Growth Rather Than Margin Growth, Aiming For Revenue Of Rs 100 Million From Electronic Chemicals In 4-5 Years.
